US Patent Issued to GENFIT on Nov. 4 for "Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists" (French Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,458,612, issued on Nov. 4, was assigned to GENFIT (Loos, France).

"Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists" was invented by Robert Walczak (Lille, France), Vanessa Legry (Emmerin, France) and Emeline Descamps (Gondecourt, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a combination therapy comprising a PPAR agonist, such as elafibranor, and a GLP-1 receptor agonist, such as semaglutide, liraglutide, exenatide, lixisenatide, albiglutide and dulaglutide, for the treatment of a condition is selected from the group consisting of non-alcoholic fatty liver disease, diabetes and...